Significance of connective tissue diseases features in pulmonary fibrosis

European Respiratory Review

Volumn 22, Issue 129, 2013, Pages 273-280

  Cottin, Vincent ^a,b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; JO 1 ANTIBODY; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SCL 70 ANTIBODY; SM ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTHROPATHY; BLOOD ANALYSIS; CAPILLAROSCOPY; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRY EYE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FIBROSIS; MUSCLE DISEASE; PATIENT CARE; PATIENT REFERRAL; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATOLOGY; SKIN DISEASE; XEROSTOMIA;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY FIBROSIS; TERMINOLOGY AS TOPIC;

EID: 84880572371     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003013     Document Type: Review

References (48)

1. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380: 689-698.
2. Antin-Ozerkis D, Rubinowitz A, Evans J, et al. Interstitial lung disease in the connective tissue diseases. Clin Chest Med 2012; 33: 123-149.
3. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
4. Navaratnam V, Ali N, Smith CJ, et al. Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis? Respir Med 2011; 105: 1925-1930.
5. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
6. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39: 661-668.
7. Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136: 23-30.
8. Le Goff B, Cherin P, Cantagrel A, et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61: 108-118.
9. Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63: 295-304.
10. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
11. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006; 12: 346-353.
12. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-250.
13. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182-1185.
14. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585-596.
15. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-1328.
16. Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1206-1208.
17. Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138: 251-256.
18. Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33: 1053-1061.
19. Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 2006; 33: 1250-1253.
20. Romagnoli M, Nannini C, Piciucchi S, et al. Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J 2011; 38: 384-391.
21. Godbert B, Wissler M-P, Vignaud JM. Desquamative interstitial pneumonia: an analytic review with emphasis on aetiology. Eur Respir Rev 2013; 22: 117-123.
22. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
23. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-548.
24. Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19: 275-283.
25. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-646.
26. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
27. Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-648.
28. Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103: 1152-1158.
29. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28: 893-896.
30. Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol 2007; 34: 1012-1018.
31. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233-241.
32. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63: 53-59.
33. Homma Y, Ohtsuka Y, Tanimura K, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration 1995; 62: 248-251.
34. Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33: 68-76.
35. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012; 51: 1278-1284.
36. Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009; 103: 1719-1724.
37. Fischer A, du Bois RM. A practical approach to connective tissue disease-associated lung disease. In: Baughman RM, du Bois RM, eds. Diffuse Lung Disease: A Practical Approach. New York, Springer Science, 2012; pp. 217-237.
38. Kim DS, Nagai S. Idiopathic nonspecific interstitial pneumonia: an unrecognized autoimmune disease?Am J Respir Crit Care Med 2007; 176: 632-633.
39. Doria A, Mosca M, Gambari PF, et al. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 2005; 32: 213-215.
40. Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum follow up of 5 years. J Rheumatol 2002; 29: 2345-2349.
41. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140: 1292-1299.
42. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106: 1040-1047.
43. Fischer A, Swigris JJ, du Bois RM, et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest 2009; 136: 1072-1078.
44. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24: 959-966.
45. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100: 124S-127S.
46. Poormoghim H, Lucas M, Fertig N, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-451.
47. Lomeo RM, Cornella RJ, Schabel SI, et al. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87: 525-527.
48. Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med 2013; 107: 249-255.